Impact of Switch Options on the Economics of Pneumococcal Conjugate Vaccine (PCV) Introduction in Indonesia

Overview

Journal Vaccines (Basel)

Date 2020 May 24

PMID 32443523

Citations 4

Authors

Auliya A Suwantika

Neily Zakiyah

Arif S W Kusuma

Rizky Abdulah

Maarten J Postma

Affiliations

Soon will be listed here.

Abstract

As one of Gavi, the Vaccine Alliance (previously the Global Alliance for Vaccines and Immunization), graduating countries, Indonesia is still eligible to access Gavi price for PCV13, PCV10 A and B. This study aims to estimate the economic impact of switch from the existing product/presentation of PCV (single-dose of PCV13) to the new product/presentation of PCV (multi-dose of PCV13, PCV10 A and B) since PCV is one of the most expensive vaccines in the Expanded Program on Immunization (EPI) schedule. Assuming that Gavi-Advance Market Commitment (AMC) price for all PCVs can be accessed in 2021, the use of multi-dose PCV13, PCV10 A and PCV10 B with Gavi-AMC price in 2021-2024 were considered as respective scenarios. The result showed that the scenario assuming the use of single-dose of PCV13 with contract price in 2019-2020 that would be switched into multi-dose of PCV10 B with Gavi-AMC price in 2021-2024 resulted in the highest potential saving, compared with other scenarios. Our analysis suggests an economic advantage to switch from single-dose into a multi-dose presentation. Vaccination coverage, vaccine price, vaccine wastage and additional Gavi-AMC vaccine costs were considered to be the most influential parameter affecting the savings in all scenarios. Applying the effectiveness of PCV13 and PCV10 A on reducing the risk for invasive pneumococcal disease (IPD), potential averted incidence of IPD in children under one year of age during 2019-2024 would be 246,164 and 105,587 in both scenarios. Despite the result confirmed that PCV13 may provide an additional benefit, a more comprehensive economic evaluation study is required to investigate further the comparison of cost-effectiveness values among all PCVs in Indonesia.

Citing Articles

Changes and determinants of pneumococcal vaccine uptake in Ethiopia.

Mamo B, Geram F, Getnet K, Bonger Z PLOS Glob Public Health. 2025; 5(1):e0004192.

PMID: 39841683 PMC: 11753632. DOI: 10.1371/journal.pgph.0004192.

Implementation challenges and real-world impacts of switching pediatric vaccines: A global systematic literature review.

Patikorn C, Kategeaw W, Perdrizet J, Li X, Chaiyakunapruk N Hum Vaccin Immunother. 2023; 19(1):2177459.

PMID: 36880656 PMC: 10026932. DOI: 10.1080/21645515.2023.2177459.

Cost-Effectiveness and Budget Impact Analyses of Pneumococcal Vaccination in Indonesia.

Suwantika A, Zakiyah N, Abdulah R, Sitohang V, Tandy G, Anartati A J Environ Public Health. 2021; 2021:7494965.

PMID: 33995536 PMC: 8096558. DOI: 10.1155/2021/7494965.

The Effect of E-Learning on the Attitude Toward Dengue Prevention and the Acceptance of Dengue Vaccination.

Ali M, Adlia A, Suwantika A Patient Prefer Adherence. 2021; 15:785-792.

PMID: 33883886 PMC: 8055251. DOI: 10.2147/PPA.S296758.

Pneumococcal Vaccination for Children in Asian Countries: A Systematic Review of Economic Evaluation Studies.

Zakiyah N, Insani W, Suwantika A, van der Schans J, Postma M Vaccines (Basel). 2020; 8(3).

PMID: 32751569 PMC: 7564215. DOI: 10.3390/vaccines8030426.

References

Richardson A, Morris D, Clarke S . Vaccination in Southeast Asia--reducing meningitis, sepsis and pneumonia with new and existing vaccines. Vaccine. 2014; 32(33):4119-23. DOI: 10.1016/j.vaccine.2014.05.062. View

Chaiyakunapruk N, Somkrua R, Hutubessy R, Henao A, Hombach J, Melegaro A . Cost effectiveness of pediatric pneumococcal conjugate vaccines: a comparative assessment of decision-making tools. BMC Med. 2011; 9:53. PMC: 3117724. DOI: 10.1186/1741-7015-9-53. View

Verani J, Domingues C, de Moraes J . Indirect cohort analysis of 10-valent pneumococcal conjugate vaccine effectiveness against vaccine-type and vaccine-related invasive pneumococcal disease. Vaccine. 2015; 33(46):6145-8. PMC: 6859415. DOI: 10.1016/j.vaccine.2015.10.007. View

Hausdorff W, Feikin D, Klugman K . Epidemiological differences among pneumococcal serotypes. Lancet Infect Dis. 2005; 5(2):83-93. DOI: 10.1016/S1473-3099(05)01280-6. View

Saokaew S, Rayanakorn A, Wu D, Chaiyakunapruk N . Cost Effectiveness of Pneumococcal Vaccination in Children in Low- and Middle-Income Countries: A Systematic Review. Pharmacoeconomics. 2016; 34(12):1211-1225. DOI: 10.1007/s40273-016-0439-3. View

Ciapponi A, Lee A, Bardach A, Glujovsky D, Rey-Ares L, Cafferata M . Interchangeability between Pneumococcal Conjugate Vaccines: A Systematic Review and Meta-Analysis. Value Health Reg Issues. 2016; 11:24-34. DOI: 10.1016/j.vhri.2015.12.001. View

Maimaiti N, Ahmed Z, Md Isa Z, Ghazi H, Aljunid S . Clinical Burden of Invasive Pneumococcal Disease in Selected Developing Countries. Value Health Reg Issues. 2018; 2(2):259-263. DOI: 10.1016/j.vhri.2013.07.003. View

. Pneumococcal vaccines WHO position paper--2012. Wkly Epidemiol Rec. 2013; 87(14):129-44. View

Rinta-Kokko H, Palmu A, Auranen K, Nuorti J, Toropainen M, Siira L . Long-term impact of 10-valent pneumococcal conjugate vaccination on invasive pneumococcal disease among children in Finland. Vaccine. 2018; 36(15):1934-1940. DOI: 10.1016/j.vaccine.2018.03.001. View

10.

Andrews N, Waight P, Burbidge P, Pearce E, Roalfe L, Zancolli M . Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study. Lancet Infect Dis. 2014; 14(9):839-46. DOI: 10.1016/S1473-3099(14)70822-9. View

11.

Diawara I, Zerouali K, Katfy K, Zaki B, Belabbes H, Najib J . Invasive pneumococcal disease among children younger than 5 years of age before and after introduction of pneumococcal conjugate vaccine in Casablanca, Morocco. Int J Infect Dis. 2015; 40:95-101. DOI: 10.1016/j.ijid.2015.09.019. View

12.

Hu J, Sun X, Huang Z, Wagner A, Carlson B, Yang J . Streptococcus pneumoniae and Haemophilus influenzae type b carriage in Chinese children aged 12-18 months in Shanghai, China: a cross-sectional study. BMC Infect Dis. 2016; 16:149. PMC: 4831093. DOI: 10.1186/s12879-016-1485-3. View

13.

Urbancikova I, Prymula R, Goldblatt D, Roalfe L, Prymulova K, Kosina P . Immunogenicity and safety of a booster dose of the 13-valent pneumococcal conjugate vaccine in children primed with the 10-valent or 13-valent pneumococcal conjugate vaccine in the Czech Republic and Slovakia. Vaccine. 2017; 35(38):5186-5193. DOI: 10.1016/j.vaccine.2017.07.103. View

14.

Sings H, De Wals P, Gessner B, Isturiz R, Laferriere C, McLaughlin J . Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Invasive Disease Caused by Serotype 3 in Children: A Systematic Review and Meta-analysis of Observational Studies. Clin Infect Dis. 2018; 68(12):2135-2143. PMC: 6541704. DOI: 10.1093/cid/ciy920. View

15.

Deceuninck G, De Serres G, Boulianne N, Lefebvre B, De Wals P . Effectiveness of three pneumococcal conjugate vaccines to prevent invasive pneumococcal disease in Quebec, Canada. Vaccine. 2015; 33(23):2684-9. DOI: 10.1016/j.vaccine.2015.04.005. View

16.

Jokinen J, Rinta-Kokko H, Siira L, Palmu A, Virtanen M, Nohynek H . Impact of ten-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in Finnish children--a population-based study. PLoS One. 2015; 10(3):e0120290. PMC: 4364013. DOI: 10.1371/journal.pone.0120290. View

17.

. Measles vaccines: WHO position paper – April 2017. Wkly Epidemiol Rec. 2017; 92(17):205-27. View

18.

Johansson Kostenniemi U, Palm J, Silfverdal S . Reductions in otitis and other respiratory tract infections following childhood pneumococcal vaccination. Acta Paediatr. 2018; 107(9):1601-1609. DOI: 10.1111/apa.14345. View

19.

Desmet S, Peetermans W, Lagrou K . Switch in childhood pneumococcal vaccine in Belgium. Lancet Infect Dis. 2018; 18(9):945-946. DOI: 10.1016/S1473-3099(18)30484-5. View

20.

Cernuschi T, Furrer E, Schwalbe N, Jones A, Berndt E, McAdams S . Advance market commitment for pneumococcal vaccines: putting theory into practice. Bull World Health Organ. 2012; 89(12):913-8. PMC: 3260895. DOI: 10.2471/BLT.11.087700. View